Therapeutic Response Statement (Sensitivity) Deprecated

This therapeutic response statement Supports the relationship that ER negative, HER2-negative, and PR negative status confers therapeutic sensitivity to Carboplatin, Gemcitabine in patients with Invasive Breast Carcinoma.

The Republic of Ireland's Health Service Executive (HSE) has approved gemcitabine in combination with carboplatin (AUC2) - 21 days for reimbursement as a treatment option for the treatment of locally recurrent metastatic triple negative breast cancer.

This statement is based on a regulatory approval from the Health Service Executive:

Treatment of locally recurrent metastatic triple negative breast cancer.

Citation

Gemcitabine and CARBOplatin (AUC2) Therapy - 21 days, 2026, version number 6, NCCP National SACT Regimen, NCCP, viewed 02/08/2026, https://healthservice.hse.ie/documents/6832/430_v5_GemcarboAUC2_csa5PxW.pdf

Contributions

Date	Contributor	Description
2024-01-16	Van Allen lab	Adding HSE approvals for reimbursement to database
2017-06-14	Health Service Executive	Indication approved for reimbursement.